- Planters Peanut Products Under Recall Due to Listeria Risk
- That ‘New Car Smell’ Could Be Toxic Carcinogens
- Gene Discovery Points to a New Form of Alzheimer’s
- Scientists May Have Located Your Brain’s ‘Neural Compass’
- Almost All Counterfeit Oxycontin Pills Contain Fentanyl
- A Parent’s Watchful Eye Does Keep Kids From Drugs, Alcohol: Study
- AI Might Boost Detection of A-Fib
- Drug May Help Folks Kick the Vaping Habit
- Small Pump May Let Kids Stay Home As They Await New Heart
- Gene Therapy Improves Vision in People With Inherited Blindness
FDA Approves Antibiotic for Skin Infections
The U.S. Food and Drug Administration has approved the intravenous antibiotic Dalvance (dalbavancin) to treat methicillin-resistant Staphylococcus aureus (MRSA) and other potentially deadly bacterial skin infections resistant to older antibiotics.
Dalvance was given priority review and designated a “Qualified Infectious Disease Product” since it’s meant to treat serious bacterial or fungal infections, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in clinical studies involving nearly 1,300 people with acute bacterial skin infections. The most common side effects were nausea, headache and diarrhea. Study participants who took Dalvance also showed a higher-than-expected incidence of elevated liver enzymes in one screening test, the agency said.
Dalvance is marketed by Durata Therapeutics of Chicago.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.